Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Aytu Bioscience Inc (NQ: AYTU)
4.540 USD  +0.310 (+7.33%)
Official Closing Price  /  Updated: 5:29 PM EDT, Aug 17, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 214,600
Open 4.200
Bid (Size) 4.380 (13)
Ask (Size) 5.480 (2)
Prev. Close 4.230
Today's Range 4.110 - 4.950
52wk Range 0.2330 - 6.960
Shares Outstanding 35,883,069
Dividend Yield N/A
Performance
YTD
+96.54%
+96.54%
1 Month
+1521.43%
+1521.43%
3 Month
+1173.49%
+1173.49%
6 Month
+260.32%
+260.32%
1 Year
-19.65%
-19.65%
Top News
More News
Aytu BioScience Announces Accelerated Launch of ZolpiMis(TM) in the U.S.
from ACCESSWIRE
Aytu BioScience Announces Effectiveness of 1-for-20 Reverse Stock Split
from ACCESSWIRE
More News
Read More
Aytu BioScience Announces Enrollment of First Twenty Patients in the Natesto(R) Spermatogenesis Study
from ACCESSWIRE
Aytu BioScience Announces 7 Presentations of Clinical Findings for its Proprietary MiOXSYS(R) System at the 34th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE)
from ACCESSWIRE
Aytu BioScience Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist(TM) to Expand Company's Commercial-Stage Product Portfolio
from ACCESSWIRE
Aytu BioScience, Inc. to Present at the 8th Annual LD Micro Invitational Investor Conference
from ACCESSWIRE
Aytu BioScience Provides Fiscal Third Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
from ACCESSWIRE
Aytu BioScience CEO Issues Letter to Shareholders
from ACCESSWIRE
Aytu BioScience to Report Fiscal Third Quarter 2018 Results and Business Update
from ACCESSWIRE
Aytu BioScience Featured in Local ABC News Segment (VIDEO): "UM Doctors Test New Medication for Treating Men with Low Testosterone; Nasal Testosterone Gel doesn't Appear to have Negative Side Effects,
from ACCESSWIRE
Technical Perspectives on Biotech Stocks -- Axovant Sciences, Aytu BioScience, BeiGene, and Bellicum Pharma
from PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.